| Old Articles: <Older 5931-5940 Newer> |
|---|
 |
The Motley Fool
October 7, 2009
Robert Steyer |
Acorda's Upcoming Excitement Acorda is seeking FDA approval for a pill to improve the walking ability of multiple sclerosis patients.   |
The Motley Fool
October 7, 2009
Jim Mueller |
Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble. |
The Motley Fool
October 2, 2009
Brian Orelli |
A Plasma-tastic IPO Talecris Biotherapeutics debuted on the public markets yesterday, raising $950 million for the company. That's the second largest IPO of the year so far. |
The Motley Fool
October 2, 2009
Brian Orelli |
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. |
BusinessWeek
October 1, 2009 |
Stalking the Future J&J lost patent protection on epilepsy and schizophrenia drugs worth $7 billion last year. These new drugs, if cleared by the FDA, could help offset the damage. |
The Motley Fool
October 1, 2009
Robert Steyer |
For Drugmakers, It's All In or Get Out The Solvay-Abbott deal illustrates why conglomerates are getting out of the prescription-drug business. |
The Motley Fool
October 1, 2009
Anders Bylund |
Why I'm Invested in Tysabri and Elan This Motley Fool analyst has investigated Elan both as an investor and a patient. What's his verdict on the company? |
The Motley Fool
October 1, 2009
Brian Orelli |
Geez, Lighten Up, Mr. Market! Investors dish out undue punishment to Onyx's stock. |
BusinessWeek
September 30, 2009
Arlene Weintraub |
J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D. |
Inc.
October 1, 2009
Adam Bluestein |
The Future of the Human Body Ten innovations that will improve quality of life - and bring down health care costs. |
| <Older 5931-5940 Newer> Return to current articles. |
